Growth Metrics

Aurinia Pharmaceuticals (AUPH) Cash from Investing Activities (2020 - 2025)

Aurinia Pharmaceuticals' Cash from Investing Activities history spans 6 years, with the latest figure at -$36.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 193.71% year-over-year to -$36.8 million; the TTM value through Dec 2025 reached -$32.8 million, down 183.46%, while the annual FY2025 figure was -$32.8 million, 183.46% down from the prior year.
  • Cash from Investing Activities reached -$36.8 million in Q4 2025 per AUPH's latest filing, down from -$13.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $49.2 million in Q1 2024 to a low of -$67.2 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is -$8.2 million, with a median of -$8.4 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: surged 2631.8% in 2022, then crashed 588.69% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$5.5 million in 2021, then soared by 45.0% to -$3.0 million in 2022, then tumbled by 107.32% to -$6.3 million in 2023, then surged by 726.87% to $39.2 million in 2024, then tumbled by 193.71% to -$36.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Cash from Investing Activities are -$36.8 million (Q4 2025), -$13.8 million (Q3 2025), and -$13.3 million (Q2 2025).